🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — March 18, 2026

The 13 filings reveal robust M&A and SPAC activity centered on business combinations, extensions, and niche sector acquisitions, with 10/13 involving SPACs showing persistence amid challenges like high redemptions (Voyager: 25.2M shares redeemed, trust at $885k) and one termination (Quartzsea due to CSRC delays). Positive divestitures and acquisitions dominate non-SPAC activity: TriMas $1.45B Aerospace sale yields $1.2B for growth/buybacks; BlockchAIn completes combo with $22.9M rev/$5.7M NI data center targeting AI expansions 2026-27; cannabis M&A surges via Grown Rogue (60% cost savings, Q2 2026 ops) and Global Asset (license options). No period-over-period declines reported across filings (e.g., BlockchAIn 2024 metrics strong, TriMas no quantitative drops); forward looks cluster in Q2-Q4 2026 for operations/expansions. Portfolio trends: Neutral routine SPAC mechanics (unit separations in 2, extensions in 3) mask bullish niche growth in AI/HPC, cannabis, packaging; bearish regulatory hurdles in PRC-related deals. Implications: Capital recycling fuels buybacks/acquisitions; monitor SPAC closings for dilution risks, alpha in post-combo trading (e.g., AIB ticker).

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 18, 2026

Across 50 overnight SEC filings, overarching themes include robust revenue growth in select consumer, tech services, and royalty firms (e.g., TSS +66% YoY, Bob's Discount +16.8% YoY, XOMA +83% YoY revenues) contrasting with persistent losses and margin pressures in small-caps and biotechs (e.g., NRHI net loss +2-6% YoY, Harte Hanks revenues -13.9% FY). M&A and proxy activity dominates with supplements for Heritage Commerce/CVB merger amid lawsuits, Two Harbors/UWM, and StableCoinX SPAC, signaling heightened litigation risks but on-track closings. Capital allocation trends favor buybacks (TSS, XOMA $16M, News Corp $1B program) and dividends (Heartland Express), while forward-looking catalysts cluster in Q2-H2 2026 (XOMA trials, Magnum 3-5% organic growth targets). Portfolio-level patterns show 7/12 detailed 10-Ks with mixed sentiment, averaging +20% revenue growth but frequent net loss widening due to op ex surges (Vyome +790% YoY). Sector outliers include strong consumer recovery (Bob's comp sales +7.7%) and ETF launches (Morgan Stanley Bitcoin Trust). Market implications point to alpha in growth outperformers and merger arb, with caution on dilution/control risks (Cyber Enviro-Tech, Laser Photonics).

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 17, 2026

FDA approved four standard ANDA generics on March 10-11, 2026—CEVIMELINE HYDROCHLORIDE (Zydus Lifesciences), BRIMONIDINE TARTRATE (Gland), LIRAGLUTIDE (Biocon Pharma), and METFORMIN HYDROCHLORIDE/SITAGLIPTIN (Apotex Inc)—all original approvals with no special designations or priority review. This 100% neutral cluster signals routine pipeline execution for generics sponsors but no novel innovation or high-impact catalysts. Two diabetes-related approvals (Liraglutide, Sitagliptin combo) highlight modest erosion potential in that segment amid pricing risks.

4 total filings
· daily

New Drug Approvals (Original) — March 17, 2026

Four ANDA generic approvals on March 10-11, 2026, for Zydus Lifesciences, Gland, Biocon Pharma, and Apotex Inc., all under standard review with no special designations, signal routine portfolio expansions for generics sponsors. Neutral implications dominate due to lack of novel features, therapeutic details, or premium positioning, with two approvals in diabetes-related drugs (Liraglutide, Metformin/Sitagliptin combo). Cluster indicates FDA batch processing efficiency but heightens generic competition risks without quantified market impacts.

4 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 17, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader equity exposure), mixed financial results dominate, with 12/50 showing YoY revenue growth averaging +25% driven by acquisitions (e.g., Intelligent Protection +2050%, ClearPoint +18%), offset by declines in 8/50 averaging -20% (e.g., Telesat -26.8%, Skkynet -34%). Margin compression is evident in 7/15 detailed financials (avg -200 bps, e.g., lululemon -260 bps), while gross margins held steady in others like ClearPoint at 61%. Capital allocation trends favor buybacks (Coca-Cola Europacific 356k shares) and redemptions (Wells Fargo Series BB), with M&A active (Brookfield $2B acquisitions, ClearPoint IRRAS). Forward-looking catalysts include ClearPoint's 2026 revenue guide $52-56M (+42% midpoint), Monte Rosa cash to 2029, and SPAC extensions (Pelican, Israel Acquisitions to Apr 2026). Board enhancements signal conviction (lululemon Chip Bergh, Peloton Sarah Robb O’Hagan), but biotech/consumer names like lululemon show regional divergences (China +29% vs Americas -1%). Portfolio implication: Favor acquisition-driven growers amid margin pressures; monitor SPAC redemptions and Q1 guidance.

33 high priority 17 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 17, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (March 17, 2026), dominant themes include accelerating bank M&A with regulatory approvals for UBFO/CWBC and Mechanics/HomeStreet mergers driving asset/deposit growth (e.g., +36% YoY) but offset by NIM compression (Bank7 -17bps, Mechanics +12bps mixed) and rising provisions; explosive revenue surges post-acquisitions (INTELLIGENT PROTECTION +2050% YoY to $23.6M, Phoenix Energy +144% to $687M); SPAC distress with extensions (AlphaTime trust down to $4.8M from heavy redemptions) and LOIs for financing. Period-over-period trends reveal mixed revenue growth (8/20 financials showed +10-800% YoY boosts from deals, 6 declined >10%), margin pressures (Urban One EBITDA -38%, Bank7 NIM -17bps), but positive guidance in industrials (Andersen +14-15% rev FY26, Phoenix 15.5-16.8M Boe). Capital allocation leans shareholder-friendly (dividends at First Guaranty 131st consecutive, buybacks at New Peoples 500k shares, IZEA $10M program); 15+ proxy filings signal Q2 governance catalysts. Implications: Favor M&A beneficiaries and high-growth acquirers amid sector consolidation, monitor SPAC deadlines and delistings like Urgent.ly.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 17, 2026

The three filings in the USA S&P 500 Energy intelligence stream highlight divergent paths: two positive 425 filings on AParadise Acquisition Corp.'s $1.3B SPAC merger with Enhanced Games (sports innovation with PEDs under medical supervision), signaling bullish investor interest via Accelerate Arbitrage Fund's long position, contrasted by Idaho Copper Corp.'s mixed 10-K showing pre-revenue status with zero revenue FY2026 vs FY2025, 44% YoY operating expense decline to $2.6M, and 40% net loss improvement to $3.1M, but critically low cash at $24K (down from $101K) and widening stockholders' deficit to $6.5M. Period-over-period trends reveal cost discipline at Idaho (professional fees -39%, stock-based comp -51%, rent -89%) amid liquidity erosion, with no revenue growth across filings underscoring pre-commercial stages. Key developments include Enhanced Games' May 2026 Las Vegas debut and Abu Dhabi training, positioning AParadise for catalysts, while Idaho's stable $3.13M bond liabilities and $2.31M accrued interest flag balance sheet risks. Portfolio-level patterns show innovation-driven SPAC optimism vs resource extraction distress, with positive sentiment dominating (2/3 filings) but materiality highest for Idaho (9/10). Market implications favor event-driven plays in AParadise amid energy transition themes (e.g., athlete health tech parallels), while urging caution on Idaho's near-term survival.

3 high priority 3 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 17, 2026

Across 50 diverse SEC filings (despite Financials stream focus, including banks, asset managers, SPACs, industrials, biotech), overarching themes include robust M&A/SPAC activity (e.g., Victory Capital's improved Janus Henderson bid, bank mergers like UBFO/CWBC), mixed revenue growth with outliers like Energy Vault's 340% YoY surge and Mechanics Bancorp's 817% net income jump post-merger, but persistent margin pressures and widening losses in media/retail (Urban One -16.5% YoY rev). Period-over-period trends show 12/25 reporting companies with revenue growth averaging +45% YoY where positive, but 8/20 with margin compression (avg -150bps, e.g., Xerox -440bps gross), and Adjusted EBITDA improvements in 7 cases (e.g., Citi Trends +$26M FY YoY). Financials subset (Mechanics, Bank7, Victory, T Rowe, TWO Harbors) highlights asset/deposit growth (+36% YoY) and accretive deals, offset by NIM declines (-12bps to -117bps). Critical developments: regulatory approvals advancing bank mergers (Q2 2026 closes), SPAC extensions/mergers, and positive guidance (Energy Vault 30% 2026 rev growth). Portfolio implications: overweight growing financial consolidators, monitor SPAC redemptions/deadlines for dilution risks, favor revenue accelerators amid macro uncertainty.

34 high priority 16 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 17, 2026

Across 50 8-K filings from March 17, 2026, dominant themes include widespread executive and board changes (28 instances, with 18 positive appointments/promotions outweighing 10 neutral retirements/resignations), aggressive financing via convertible notes/debt (e.g., $4.3M Tenon, $500M Indivior, $124K American Rebel), and key M&A/contract wins (Fulgent $56.9M acquisition, Duos $176M GPUaaS over 36 months). Period-over-period data is sparse but highlights Bicycle Therapeutics' Q4 revenue surge +$44.3M YoY (to $48M) and FY +$37.3M (to $72.6M), offset by FY net loss widening to $219M (+$50M YoY) from R&D; no broad margin compression but dilution risks in 8 small-cap debt deals. Capital allocation shines with First Industrial's $250M open-ended buyback and Beazer Homes' 44% credit facility expansion to $525M. Sector patterns favor biotech/health (positive sentiment in 6/7 filings) and infrastructure (Duos, DTE/Google deals), signaling management conviction via experienced hires amid liquidity maneuvers. Implications: Bullish for growth-stage firms securing capital/contracts, cautious on dilution-heavy financings; portfolio tilt toward health/tech with catalysts like Duos' 75MW expansion and Clene's NIH-funded ALS program through Aug 2026.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 17, 2026

Across the 8 filings in the USA S&P 500 Technology stream, dominant themes include advancing SPAC de-SPAC mergers (AParadise with Enhanced Games, dMY Squared with Horizon Quantum) and bank-tech adjacent mergers (Community West Bancshares), alongside restructuring at PSQ Holdings with strong revenue growth but cash burn, proxy preparations at Altimmune, and shelf registration post-divestitures at Planet Green. Period-over-period trends highlight PSQ's revenue surge (+81% FY YoY, +109% Q4 YoY) and loss improvements (-37% FY net loss YoY), contrasted by sharp cash declines (-59% YoY to $14.6M) and equity drops (-50% to $13.4M), with no other filings showing financial metrics but positive merger progress. Critical developments like regulatory approvals, shareholder votes, and 2026 event timelines (e.g., Enhanced Games May 2026) signal near-term catalysts amid mixed sentiment (4 positive, 3 mixed, 1 neutral). Portfolio-level patterns reveal M&A momentum in 4/8 filings, operational restructurings for cost savings (PSQ staff cuts >40%, $8M annualized savings), and divestitures of underperformers (Planet Green), implying sector focus on consolidation and efficiency despite cash pressures. Market implications favor event-driven trades around Q1-Q2 2026 catalysts, with relative outperformance in revenue growers like PSQ vs. stagnant peers.

4 high priority 4 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 17, 2026

Across the 8 NASDAQ-100 related filings dated March 17, 2026, dominant themes include M&A momentum with SPAC and bank mergers advancing toward Q2 2026 closures, explosive post-acquisition revenue growth at IPM (2050% YoY to $23.6M FY2025), and early product wins like AITX's order, contrasted by mixed profitability signals and routine governance actions. Period-over-period trends highlight IPM as a hypergrowth outlier with Q4 revenue +2092% YoY to $6.1M but -1.7% QoQ decline, net losses improving 77% YoY to $2.0M annually, positive Q4 Adjusted EBITDA of $5K, and operating cash flow turning positive; no comparable metrics in other filings limit broader aggregation but underscore IPM's relative outperformance. Critical developments like regulatory approvals for CWBC-USB merger and AParadise-Enhanced Games $1.3B combination signal near-term catalysts, while IPM's $400K buyback (76% executed) and zero long-term debt reflect prudent capital allocation. Portfolio-level patterns show 4/8 filings positive on growth/M&A, 2 mixed on IPM's losses/litigation, and 2 neutral on governance/shelf, implying bullish M&A tailwinds but watch for dilution/integration risks. Overall, actionable intelligence favors positioning ahead of March-April shareholder votes and May 2026 Enhanced Games debut, with IPM as a high-beta turnaround play.

4 high priority 4 medium 8 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 17, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (March 17, 2026), dominant themes include robust M&A and SPAC activity in finance (e.g., bank mergers like United Security/Community West and Two Harbors/UWM), explosive revenue growth in energy storage (Energy Vault +340% YoY) and select tech/biotech, offset by margin compression and net loss widening in 12/50 companies averaging -25% YoY net income growth where reported. Period-over-period trends show 18 companies with revenue growth >20% YoY (avg +85%), but 14 with margin contraction (avg -250 bps) and 10 with cash burn acceleration (avg +35% YoY); banks exhibit deposit growth (+36% YoY Mechanics) amid NIM stability/declines. Forward-looking catalysts cluster in Q2 2026 (e.g., merger closings, Phase 3 trials), with capital allocation favoring debt refinancings (Indivior $500M notes) and buybacks/dividends ($1.69B CF Industries returns). Mixed sentiment prevails (28/50), signaling portfolio-level caution on profitability amid growth; outliers like BW Industrial IPO ($17.1M proceeds) and Vireo M&A highlight alpha in industrials/cannabis. Implications: Rotate into high-backlog growth (Energy Vault $1.3B) and monitor bank consolidations for synergies, while hedging media/tech declines (Urban One -16% rev, Baidu -3%).

30 high priority 20 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 17, 2026

Across 50 SEC filings dated March 17, 2026, dominant themes include active SPAC mergers/de-SPACs (e.g., AParadise/Enhanced Games, Tri Pointe/Sumitomo, Pelican/Greenland), biotech advancements (Monte Rosa positive Phase 1 data, Cortigent IPO for brain implants), and retail/industrial turnarounds (Citi Trends +9% YoY sales, Ethos +52% revenue), contrasted by mixed financials (Mechanics Bancorp +817% net income from merger gain but rising provisions) and infrastructure stability (Brookfield +9.8% revenue). Period-over-period trends show revenue growth averaging +20% YoY in reporting firms (e.g., Citi Trends +8.9% FY sales, Dragonfly +15.8% FY), but margin pressures in 4/8 cases (Dragonfly -260bps FY gross margin, PURE mixed product lines) and net losses narrowing in biotechs/small caps (PURE -16% 6m loss). Capital allocation leans conservative (Citi Trends zero debt, Dragonfly $8.9M cost savings), with forward-looking catalysts like IPOs, FDA milestones, and merger votes driving near-term volatility. Portfolio-level patterns highlight biotech/healthcare outperformance (5/7 positive/mixed with clinical wins) vs neutral proxy/compliance noise (15+ ABS 10-Ks). M&A activity signals consolidation in homes/financials, while emerging IPOs (Cortigent $15M, BW Industrial $17M) offer growth entry points amid controlled company structures.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 17, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with cross-sector context from retail, hotels, airlines, and adjacent), key themes include robust revenue growth in 8/14 reporting companies (avg +45% YoY, led by Dragonfly +15.8%, Fold +34%, Marwynn +122%) offset by widespread margin compression (avg -200bps) and widening losses (e.g., Fold op loss to $27.7M, SafeSpace -41% YoY), signaling cost pressures amid RV/auto softness and ops disruptions. Capital allocation remains shareholder-friendly with new buybacks ($250M First Industrial, Kforce 10b5-1 plan, CF $1.37B repurchases), steady dividends (Waterstone quarterly, First Guaranty 131st consecutive), and M&A activity ($800M+ Infinity upstream, Fulgent $56.9M assets, Farmer Bros merger). Proxy season ramps up with 15+ AGMs in April-May 2026, highlighting board refreshers and comp votes. Forward guidance mixed: Dragonfly targets EBITDA positivity at $70M run-rate, Frontier Q1 loss $0.32-0.44 amid fuel spikes. Portfolio-level: 6/10 high-materiality filings show mixed sentiment, with hotels/entertainment stable but airlines volatile; actionable now on buybacks amid undervalued growth names.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 17, 2026

Across 41 diverse SEC filings labeled under USA S&P 500 Healthcare (though spanning retail, biosciences, energy, finance, and more), overarching themes include modest revenue growth averaging ~12% YoY in 8/41 reporting companies (e.g., Lifeway +14%, PURE Bioscience +22%, Zeo +33%), offset by persistent net losses in biosciences and cash burn concerns; margin expansions noted in standouts like Citi Trends (+210bps FY to 39.6%) and Lifeway (+140bps to 27.4%). Healthcare-adjacent biosciences (7 filings) show revenue up avg 15% YoY but mixed sentiment with narrowing losses (PURE -16%, Cibus -53%) amid clinical catalysts and M&A (Rallybio merger). Capital allocation leans toward buybacks (News Corp $1B program, New Peoples 500k shares) and dividends (Waterstone quarterly), while energy names like New Fortress face severe restructuring (debt cut to $527.5M, shareholder dilution to 35%). Critical developments: bioscience efficiency gains and product launches (Cibus rice traits 2027-28), SPAC mergers for growth (Abra $10B AUM target 2027), but restatements/restatements signal control weaknesses. Portfolio implications: selective opportunities in high-growth biosciences/turaround retail, caution on cash-strapped microcaps and leveraged restructurings.

19 high priority 22 medium 41 total filings
· daily

Global High-Priority Regulatory Events — March 17, 2026

The 50 filings reveal a surge in SPAC/de-SPAC activity (10+ filings including Black Hawk/Vesicor, AParadise/Enhanced Games, Pelican/Greenland) with promotional interviews, extension notes, and merger progress amid positive sentiment for biotech/sports innovations. Indian insolvency events dominate critically (Jaiprakash Adani resolution with shareholder wipeout, Hindustan Zinc 55.83% promoter encumbrance, Videocon/Sumeet/Value CIRP updates), signaling distressed asset opportunities but promoter control risks. Financial trends mixed: standout revenue growth (Ethos +52% YoY to $387.6M, Mechanics Bancorp NI +817% YoY to $266M post-merger, Xerox +12.9% to $7B, McEwen +13%), but margin compressions (Xerox -4.4pts to 27.1%, Brookfield op cash -8%) and debt piles (PURE $5.52M convertibles, American Rebel 15% note). Biotech/medical advances bullish (Vesicor CEO hire, Tenon $4.3M raise, NeOnc CAO), IPOs/S-1s active (Cortigent brain implants $4-6B TAM, BW Industrial $17M), capital allocation favors buybacks (First Industrial $250M). Portfolio patterns: SPAC catalysts near-term, Indian miners bearish leverage, US small caps growth via M&A/debt; implications for alpha in de-SPACs, caution on distress.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 17, 2026

The IPO Pipeline stream on March 17, 2026, captures two high-materiality filings: Rallybio Corp's S-4 for its merger with Candid Therapeutics (mixed sentiment) and AmperCap Acquisition Company's S-1 for a $125M SPAC IPO (neutral sentiment). Both entities exhibit no revenues to date, reflecting pre-operational stages with zero YoY/QoQ revenue growth and flat operational metrics, underscoring high-risk development plays. Rallybio's merger includes CVRs tied to a July 8, 2025, Recursion Pharmaceuticals deal, introducing contingent value amid post-merger compliance hurdles like 12-month Form S-3 ineligibility. AmperCap's SPAC structure deposits proceeds into a trust for a 24-month business combination window, with $2.5M underwriting discounts and $4M working capital needs. Portfolio-level patterns show biotech M&A activity intersecting with SPAC launches, signaling potential thaw in risk-on IPO markets. Critical implications include merger catalyst timing for Rallybio and SPAC pricing appetite for AmperCap, with no insider activity or capital allocation trends reported across filings.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — March 17, 2026

Across 50 SEC filings for Q4 2025/FY2025 financial results filed March 17, 2026, sentiment is predominantly mixed (25+ filings) with neutral ABS servicing compliance dominating low-materiality disclosures (15+ filings), signaling routine stability in asset-backed securities servicing but no major issues. Revenue growth trends are uneven: strong outperformers like Ethos Technologies (+52% YoY to $387.6M), Xerox (+12.9% to $7.0B), and HealthEquity (+9% to $1.31B) contrast with decliners like NextNav (-19.3%), IZEA (-13%), and Gossamer Bio (-58%), averaging modest portfolio-level growth of ~15% YoY among high-materiality names. Margin compression is widespread (e.g., Xerox gross margin -440bps to 27.1%, Academy SG&A +820bps to 26.3%), offset by loss narrowing in biotechs (Monte Rosa -47% to $38.6M loss, AN2 -31% to $35.2M) and banks (Mechanics +817% net income post-merger). Capital allocation leans conservative with dividends up in Value Line (+8% nine-month payout to $9.2M) but dilution rampant via equity raises (X4 shares +1495% to 90.9M, Oklo cash +712% to $788M). SPACs like M3-Brigade and ProCap show passive interest income gains ($4.15M, $5.66M) amid no business combinations. Biotech/pharma heavy (12 filings) highlights R&D spend persistence despite cuts, while banking/mining exhibit asset expansion but yield pressures; actionable theme is selective rotation to revenue accelerators like DTC/tech amid macro caution.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 17, 2026

Across 38 DEF 14A filings filed March 17, 2026, a dominant theme is robust 2025 performance recaps with YoY growth in key metrics—e.g., Rollins double-digit revenue/earnings/cash flow (24th consecutive revenue growth year), CF Industries net earnings $1.46B (+implied strong YoY), Archrock NI +87% YoY/EBITDA +51% YoY/margins +600bps, Ball Corp record $13.16B sales/EVA/FCF/EPS—contrasting with mixed outlooks in cyclicals like Boise Cascade (flat 2026 construction) and Polaris (headwinds/divestiture). Capital allocation emphasizes shareholder returns totaling billions (CF $1.69B buybacks/dividends, Global Payments $1.5B, Archrock $212M), signaling management conviction amid neutral-to-positive sentiment (11 positive, 4 mixed). Governance highlights include board refreshes (e.g., T. Rowe Price +2 independents, Global Payments +3), independent majorities (e.g., Ball 8/9, AutoNation independent Chair), and standard proposals for elections/say-on-pay/auditors, with 20+ virtual meetings April-May 2026 as catalysts. No widespread insider selling detected; director ownership increases noted (Gran Tierra DSUs/PSUs YoY up). Portfolio-level: Industrials/energy outperform (6/10 positive), SPACs/cyclicals lag; pay-vs-performance XBRL disclosures (15+ filings) show alignment without major declines. Implications: Favor high-return firms pre-vote catalysts, monitor extensions/divestitures for downside.

38 high priority 38 total filings